Steroid-unresponsive acute attacks of inflammatory bowel disease: Immunomodulation by tacrolimus (FK506)

American Journal of Gastroenterology

Volumn 93, Issue 10, 1998, Pages 1860-1866

  Fellermann, K ^a   Ludwig, D ^a   Stahl, M ^a   David Walek, T ^a   Stange, E F ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOMODULATING AGENT; MESALAZINE; PREDNISONE; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; ENTERITIS; FEMALE; HUMAN; ILEITIS; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; REMISSION; THRUSH; TREATMENT FAILURE; TREMOR; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; STEROIDS; TACROLIMUS; TIME FACTORS; TREATMENT FAILURE;

EID: 0032447773     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.539_g.x     Document Type: Article

References (42)

1. 1. Truelove SC, Wilts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. Br Med J 1955;2:1041-8.
2. 2. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33.
3. 3. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-5.
4. 4. Kornbluth A, Lichtiger S, Present DH, et al. Long-term results of oral cyclosporin in patients with severe ulcerative colitis: A double blind, randomized, multi-center trial. Gastroenterology 1994;106:A714.
5. 5. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-5.
6. 6. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8.
7. 7. Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996;62:594-9.
8. 8. Stephens J, Goldstein R, Crippin J, et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 1993; 25:1122-3.
9. 9. Bousvaros A, Leichtner AM, Book L, et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology 1996;111:237-43.
10. 10. Bousvaros A, Wang A, Leichtner AM. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996;23: 329-33.
11. 11. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997;92:876-9.
12. 12. Kornbluth A, Sachar DB, Salomon P. Chapter 101: Crohn's disease. Jewell DP. Chapter 102: Ulcerative colitis. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's gastrointestinal and liver disease: Pathophysiology/diagnosis/management, 6th ed. Philadelphia: W.B. Saunders, 1998:1708-58.
13. 13. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-44.
14. 14. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal anal pouch-anal anastomosis: A pouchitis disease activity index. Mayo Clin Proc 1994;69:409-15.
15. 15. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35: 360-2.
16. 16. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-66.
17. 17. Nagy G, Pronay G, Uiszaszy L. Therapeutical experiments in ulcerative colitis and Crohn's disease. Acta Med Hung 1985;42:163-74.
18. 18. Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
19. 19. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: Time for a reappraisal? Gastroenterology 1997;112:A1002.
20. 20. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis. Dig Dis Sci 1996;41:2471-6.
21. 21. Stange EF, Fleig WE, Rehklau E, et al. Cyclosporin A treatment in inflammatory bowel disease. Dig Dis Sci 1989;34:1387-92.
22. 22. Santos JV, Baudet JA, Casellas FJ, et al. Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. J Clin Gastroenterol 1995;20:207-10.
23. 23. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin. Am J Gastroenterol 1993;88: 646-9.
24. 24. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam Bowel Dis 1995;1:48-63.
25. 25. Stange EF, Modigliani R, Pena AS. European trial of cyclosporine in chronic active Crohn's disease: A 12 month study. Gastroenterology 1995;109:774-82.
26. 26. Jewell DP, Lennard-Jones JE, the Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: A multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6:499-505.
27. 27. Feagan BG, McDonald JWD, Rochon J. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994;330:1846-51.
28. 28. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol 1990;4:554-74.
29. 29. Feutren G, Mihatsch MJ, for the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-60.
30. 30. Mahadevan U, Kornbluth AA, Goldstein E, et al. Is cyclosporine (CS) induced nephrotoxicity permanent or progressive in patients with inflammatory bowel disease. Gastroenterology 1997;112:A1030.
31. 31. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK 506. Immunol Today 1992;13:136-42.
32. 32. Bierer BE. Biology of cyclosporine A and FK506. Prog Clin Biol Res 1994;390:203-23.
33. 33. Frezza EE, Tzakis A, Fung JJ, et al. Small bowel transplantation: Current progress and clinical application. Hepatogastroenterology 1996;43:363-76.
34. 34. Grant D. Current results of intestinal transplantation. Lancet 1996;347: 1801-3.
35. 35. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-94.
36. 36. Thomson AW, Carroll PB, McCauley J, et al. FK506: A novel immunosuppressant for treatment of autoimmune disease. Springer Semin Immunpathol 1993;14:323-44.
37. 37. Van Thiel DH, Carroll PB, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.
38. 38. Bousvaros A, Kirschner B, Werlin S, et al. Oral tacrolimus treatment of severe colitis in children. Gastroenterology 1997;114:A941.
39. 39. Randhawa PS, Shapiro R, Jordan ML, et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Am J Surg Pathol 1993; 17:60-8.
40. 40. Lobo AJ, Juby LD, Smith AH, et al. Effect of oral cyclosporin on renal function in Crohn's disease. Dig Dis Sci 1993;38:1624-30.
41. 41. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920-6.
42. 42. Bäckman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 1994; 57:519-25.